The FDA has approved Santarus’ daily extended-release drug Uceris to induce remission of mild to moderate active ulcerative colitis, a form of inflammatory bowel disease. The company plans to launch the drug in March and expects peak annual sales of up to $300 million. Santarus also announced plans to increase its number of sales representatives by 50 percent to 235.
Washington Drug Letter